Osimertinib相关论文
表皮生长因子受体（EGFR）基因作为重要的肿瘤驱动基因，在非小细胞肺癌（NSCLC）的发生、发展中发挥着重要作用。奥希替尼作为最新一代的EGF......
Triple administration of osimertinib followed by chemotherapy for advanced lung adenocarcinoma: A ca
BACKGROUND Osimertinib is the recommended first-line treatment for adult patients with epidermal growth factor receptor(......
第1,2代表皮生长因子受体酪氨酸激酶抑制药(EGFR-TKIs)可用于表皮生长因子受体(EGFR)基因敏感突变的非小细胞肺癌(NSCLC)患者的一......
Final Overall Survival Results from the FLAURA Trial: a Phase Ⅲ Study on Osimertinib in EGFR-Mutated
The discovery of activating mutations in epidermal growth factor receptor (EGFR) and development of first-/second-genera......
